Now accepting a limited number of new Valerian patients each quarter  ·  River Oaks, Houston

Reserve Your Assessment
All Programs Program 03  ·  HRT & TRT

Normal range is
where most people land.

It is not where you function best.

Testosterone for men, bioidentical hormones for women, with thyroid and cortisol read in the same panel. The question is never whether you fall inside a reference range — it is where in that range you actually feel like yourself.

What It Is

A reference range is
a population average.

The number printed beside your result tells you where most people your age and sex fall. It does not tell you where you function best. Two people can sit at opposite ends of the same range and lead noticeably different lives — in energy, in recovery, in how clearly they think by mid-afternoon.

Hormone optimization at Valere means finding that individual level and building a protocol around reaching and holding it. For men that usually centres on testosterone. For women it centres on estradiol, progesterone, and often low-dose testosterone. For both it includes thyroid and cortisol, because those two govern how everything else behaves and are routinely read too narrowly.

What this is not: a subscription, an algorithm, or a standard starting dose applied to whoever walks in. The panel comes first, the physician reads all of it, and the protocol follows from what it actually shows.

Read in Every Panel

Sex Hormones

Total and free testosterone, estradiol, progesterone, SHBG, LH, FSH, DHEA-S. Free matters as much as total — SHBG determines how much is actually available.

Thyroid — Fully

TSH, free T3, free T4, and reverse T3. TSH alone is the most common gap in a hormonal workup, because it tells you almost nothing about what the cells are receiving.

Cortisol

Chronically elevated cortisol competes with everything else being corrected. It is assessed rather than assumed away.

Safety Markers

Hematocrit, PSA where applicable, lipids, blood pressure, IGF-1, and metabolic markers — tracked at baseline and at every follow-up panel.

What It Is Used For

The biology is different.
So are the programs.

Male hormonal decline is gradual and largely linear. Female hormonal change is neither. Treating them with a shared template produces a poor version of both.

For Men

Testosterone Replacement

Testosterone declines roughly one percent per year after thirty. Most men are never told to measure it, and many who do are told they are "in range" while feeling nothing like themselves. Where the panel supports it, TRT is initiated at the dose and delivery method your specific results warrant — with estradiol conversion, hematocrit, PSA, and blood pressure tracked at every follow-up.

Men's Sexual Wellness Libido and function, assessed with hormonal status Men's Metabolic Health Visceral fat, lean mass, insulin sensitivity
For Women

Bioidentical Hormone Therapy

Perimenopause frequently begins years before anyone names it, and the labs can read normal throughout. Estradiol, progesterone, and where indicated low-dose testosterone are prescribed by the route and dose your panel and history support — with thyroid and cortisol assessed in the same picture, since both are commonly the missing variable.

Women's Sexual Wellness Libido, comfort, tissue health Women's Metabolic Health Body composition, energy, weight that changed

Hormone therapy is prescribed only where clinically indicated following physician evaluation, and is not appropriate for everyone. Testosterone products carry a Limitation of Use for age-related hypogonadism. Individual results vary.

How It Works

Three variables decide
how well it goes.

Not whether hormone therapy works — that question is largely settled. What determines the outcome is which hormones, by what route, and when it is started.

01

Which Hormones

Correcting one hormone while ignoring the others produces partial results and is the most common reason people report that hormone therapy "did not work" for them. Sex hormones, thyroid, and cortisol interact — the panel reads all of them together.

02

By What Route

Route and dose are not interchangeable details. Published guidance notes that transdermal administration and lower doses may carry a different risk profile than oral for some outcomes. This is a clinical decision made with you, not a default.

03

And When

For women this may be the single most underexplained variable in the entire field. Timing relative to menopause onset materially changes the benefit-risk picture — and almost nobody has it explained to them before they are asked to decide.

The Honest Conversation

You have probably been told
half of this.

The safety picture for hormone therapy has genuinely changed in recent years, in both directions. Practices tend to report the half that suits them. Here is the whole of it.

Testosterone & the Heart

What the 2025 label change did — and did not — say.

In February 2025 the FDA removed cardiovascular-risk language from the Boxed Warning across all testosterone products, following the TRAVERSE trial.

TRAVERSE enrolled 5,246 men aged 45 to 80 with hypogonadism and existing or high cardiovascular risk. Testosterone was noninferior to placebo for major adverse cardiac events.

Noninferior means not worse. The trial was not designed to show testosterone protects the heart, and it made no such finding.

A new warning about increased blood pressure was added at the same time. It applies across all testosterone products.

The FDA retained its Limitation of Use language for age-related hypogonadism. Testosterone is not approved simply for being older.

Source: FDA class-wide labeling changes for testosterone products, February 2025.

Women & the Timing Question

When you start changes the entire calculation.

Published position guidance holds that for women under sixty, or within ten years of menopause onset and without contraindications, the benefit-risk balance is favourable for vasomotor symptoms and bone loss prevention.

Beyond ten years from onset, or past sixty, that balance is described as less favourable because absolute risks rise. The same therapy, a different calculation.

Risk varies by type, dose, duration, route, timing, and whether a progestogen is used. There is no single answer that applies to every woman.

Guidance is explicit that treatment should be individualized with shared decision-making and reassessed periodically — which is exactly how it is run here.

Source: The 2022 hormone therapy position statement of The North American Menopause Society.

None of this is a reason to avoid hormone therapy. It is the reason to have it prescribed by someone who read the whole file rather than the headline.

How It Applies at Valere

The physician is the constant.
Not the algorithm.

01

Every Number, Reviewed With You

Not a portal summary and not a traffic-light chart. Your physician walks the full panel with you — what each marker means, where you sit, and what the data suggests. Most Valerian patients say it is the first time anyone has done that.

02

The Risk Conversation Happens First

Fertility implications for men who have not completed their family. Timing and route for women. Monitoring requirements for everyone. All of it before a protocol is written, not after — including when the honest recommendation is not to proceed.

03

Monitored, Then Refined

Follow-up panels at six to eight weeks, then quarterly. Estradiol conversion, hematocrit, PSA where applicable, blood pressure, and lipids tracked throughout. Most protocols need adjusting in the first cycle — that is the design working, not failing.

04

Inside a Program, Not Beside One

Nutrition, exercise, coaching, peptide support, and supplement support are assessed in the same program. Hormonal correction sets the conditions — what you do inside those conditions determines the result.

Common Questions

What Valerian patients ask
before they commit.

Normal range describes where most people your age and sex fall. It is a population statistic, not an individual target. Someone sitting at the bottom of a range can have meaningfully different energy, clarity, and recovery than the same person in the upper third. There is also the question of what was measured — a hormonal workup that captured TSH but not free T3, free T4, and reverse T3 has missed most of the thyroid picture. The question this program asks is not whether you are in range. It is where in that range you actually function.

The picture improved meaningfully in 2025 but the headline version circulating is incomplete. Following the TRAVERSE trial, the FDA removed cardiovascular-risk language from the Boxed Warning across all testosterone products. TRAVERSE enrolled 5,246 men with hypogonadism and existing or high cardiovascular risk, and found testosterone noninferior to placebo for major adverse cardiac events. Noninferior means not worse — the trial was not designed to show testosterone protects the heart and made no such finding. At the same time a new warning about increased blood pressure was added across all products, and the FDA retained its Limitation of Use language for age-related hypogonadism. Your physician reviews your full cardiovascular history and blood pressure before anything is prescribed, and tracks both throughout. Details are at FDA.gov.

You have, and much of the confusion traces to a single large study from the early 2000s whose findings were widely generalized beyond the population studied. Current published position guidance is considerably more nuanced. For women under sixty or within ten years of menopause onset, without contraindications, the benefit-risk balance is described as favourable for vasomotor symptoms and prevention of bone loss. Beyond that window it is described as less favourable because absolute risks rise. Risk also varies by type, dose, duration, route, and whether a progestogen is used. That is why there is no universal answer and why guidance calls explicitly for individualized, shared decision-making. The 2022 position statement is at PubMed.

Yes, and this is among the most important questions to raise before starting. Testosterone given from outside suppresses the body's own production of LH and FSH, which are required for sperm production. For any man who has not completed his family, that is a significant consideration rather than a footnote. Fertility-preserving alternatives exist and your physician will discuss which are appropriate for your situation. This conversation happens before any protocol is initiated — never after.

Because they routinely turn out to be the actual problem. Thyroid governs the metabolic rate at which every cell operates, and a workup that stops at TSH misses what the cells are actually receiving — free T3, free T4, and reverse T3 tell that part of the story. Chronically elevated cortisol competes with sex hormones and can undo much of what a protocol is trying to achieve. Correcting testosterone or estradiol while leaving either unaddressed is the most common reason people report that hormone therapy did not work for them.

Often, though the honest answer depends on why you started. Where a genuine deficiency exists, replacement addresses an ongoing condition rather than a temporary one, and stopping generally returns you to where you began. For women, guidance recommends periodic reassessment of the benefit-risk balance rather than an indefinite continuation by default. What matters more than duration is that someone is actually monitoring — panels, markers, and a physician reviewing whether continuing still makes sense for you specifically.

No. Valere operates as a private-pay practice. That is what allows the panel to be as comprehensive as it is, the physician time to be what it is, and the follow-up and coaching to be built in rather than billed for separately. An insurance-driven model would not support a ninety-minute assessment or a full thyroid and cortisol workup on someone whose TSH reads normal. Payment plans and membership options are available.

Hormone therapy is prescribed only where clinically indicated following physician evaluation and is not appropriate for everyone. Testosterone products carry a Limitation of Use for age-related hypogonadism and a warning regarding increased blood pressure. All clinical decisions, including eligibility, rest solely with the licensed physician. Individual results vary. This page is educational and does not constitute medical advice — please consult your primary care provider.

Your numbers will tell us
what your symptoms cannot.

Your assessment begins with the full panel — sex hormones, thyroid, cortisol, and safety markers. Your physician reviews every one of them with you.

Reserve Your Assessment

Private  ·  By appointment only  ·  River Oaks, Houston